– Oral Plasma Kallikrein Inhibitor Data in a Preclinical Model of
Retinal Edema to be Presented –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
that data in support of KalVista’s ongoing development in diabetic
macular edema (DME) has been accepted for oral presentation at The
Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual
Meeting on May 1, 2018 in Honolulu, Hawaii.
“We look forward to presenting oral plasma kallikrein inhibitor data at
ARVO 2018,” said Andrew Crockett, Chief Executive Officer of KalVista.
“The potential to treat retinal edema orally would be a groundbreaking
option for patients and we are pleased to share these findings with the
medical and patient communities.”
The oral presentation details are as follows:
Novel Oral Plasma Kallikrein (PKal) Inhibitor KV123833 Blocks
VEGF-Mediated Retinal Vascular Hyperpermeability in a Murine Model of
Session: Neovascularization and Vascular
Session Date/Start Time: May 1, 2018 at
3:45 PM in Room 314
About KalVista Pharmaceuticals, Inc.
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule protease
inhibitors for diseases with significant unmet need. The initial focus
is on inhibitors of plasma kallikrein, which is an important component
of the body’s inflammatory response and which, in excess, can lead to
increased vascular permeability, edema and inflammation. KalVista has
developed a proprietary portfolio of novel, small molecule plasma
kallikrein inhibitors initially targeting hereditary angioedema (HAE)
and diabetic macular edema (DME). The Company has created a structurally
diverse portfolio of oral plasma kallikrein inhibitors, and is advancing
multiple drug candidates into Phase 1 clinical trials for HAE.
KalVista’s most advanced program, an intravitreally administered plasma
kallikrein inhibitor known as KVD001, has successfully completed its
first-in-human study in patients with DME and began a Phase 2 clinical
trial in 2017.
For more information, please visit www.kalvista.com.
This press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will" and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding, our
cash runway and future clinical trial timing and results. Further
information on potential risk factors that could affect our business and
its financial results are detailed in the annual report on Form 10-K
filed on July 27, 2017, our most recent Quarterly Report on Form 10-Q,
and other reports as filed from time to time with the Securities and
Exchange Commission. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future
developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180418005143/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Leah Monteiro, 857-999-0808
Corporate Communications & Investor Relations